Staphylococcus aureus in children: a persistent threat with evolving challenges

Staphylococcus aureus is the leading invasive bacterial pathogen in children across the U.S. and many parts of the world, surpassing diseases previously dominated by Streptococcus pneumoniae and Haemophilus influenzae. Recent trends in pediatric S. aureus infections reveal a shift from methicillin-resistant S. aureus (MRSA) to methicillin-susceptible S. aureus (MSSA), which now accounts for the majority of invasive infections. Despite this shift, the severity of infections caused by MSSA rivals that of MRSA, challenging current infection control practices that primarily focus on MRSA prevention.

New antimicrobials have been developed to address resistant S. aureus strains, with promising options such as ceftaroline, a fifth-generation cephalosporin, and long-acting glycopeptides like dalbavancin. These innovations provide new hope for treating both MRSA and MSSA, though pediatric data remain limited. Novel therapeutic approaches targeting virulence factors, such as quorum-quenching antivirulence compounds and monoclonal antibodies, represent an emerging frontier in antistaphylococcal therapy, offering alternative strategies to traditional antimicrobial treatments.

Vaccine development against S. aureus has faced numerous setbacks over the last century. However, recent research focuses on targeting staphylococcal toxins, such as alpha-hemolysin and leukocidins, which play key roles in the pathogen’s evasion of host immune defenses. While a successful vaccine remains elusive, ongoing research into multivalent vaccines and passive immunization strategies holds promise for reducing the burden of severe, invasive S. aureus disease in children.